TY - JOUR T1 - Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation? AU - Ji,Young Sok, AU - Lee,Min Sung, AU - Min,Chang Wook, AU - Park,Seong Kyu, AU - Kim,Se Hyung, AU - Yun,Jina, AU - Kim,Hyun Jung, AU - Kim,Kyoung Ha, AU - Kim,Chan Kyu, AU - Lee,Kyu-Taek, AU - Won,Jong-Ho, AU - Hong,Dae Sik, Y1 - 2016/03/28/ PY - 2015/07/22/received PY - 2015/09/06/revised PY - 2015/09/13/accepted PY - 2016/3/29/entrez PY - 2016/3/29/pubmed PY - 2017/5/16/medline KW - Antithymocyte globulin KW - Fludarabine KW - Graft vs host disease KW - Hematopoietic stem cell transplantation KW - Related donor SP - 750 EP - 61 JF - The Korean journal of internal medicine JO - Korean J Intern Med VL - 31 IS - 4 N2 - BACKGROUND/AIMS: There is controversy about the prophylactic effect of anti-thymocyte globulin (ATG) on graft versus host disease (GVHD) in the setting of matched related-donor hematopoietic stem cell transplantation (HSCT). This study assessed the inf luences of ATG on the incidences of acute and chronic GVHD and other clinical outcomes in matched related-donor HSCT. METHODS: Sixty-one patients received allogeneic HSCT from human leukocyte antigen-matched, related donors. Patients received busulfan/fludarabine conditioning regimens and standard GVHD prophylaxis with or without additional ATG. RESULTS: There was no significant difference in the cumulative incidences of overall acute GVHD, grade II to IV acute GVHD at day 100, and chronic GVHD during the follow-up period between the ATG and non-ATG groups. Three-year overall survival rates were very similar, but three year disease-free survival of the non-ATG group was higher than that of the ATG group (56.2% for ATG vs. 63.1% for non-ATG, p = 0.597). Relapse rate at 3 years in the ATG group was slightly higher than that of the non-ATG group (37.5% vs. 20%, p = 0.29). Non-relapse mortality rate at 3 years was lower in the ATG group (6.25% vs. 15.6%, p = 0.668). CONCLUSIONS: Although the addition of ATG doesn't guarantee a reduction in the incidences of acute and chronic GVHD, pre-transplantation ATG may result in lower non-relapse mortality in the context of matched related-donor HSCT with a busulfan/fludarabine conditioning regimen. However, caution is needed when using ATG because of a possibility to increase relapse rate. SN - 2005-6648 UR - https://www.unboundmedicine.com/medline/citation/27017944/Does_anti_thymocyte_globulin_have_a_place_in_busulfan/fludarabine_conditioning_for_matched_related_donor_hematopoietic_stem_cell_transplantation L2 - https://dx.doi.org/10.3904/kjim.2015.234 DB - PRIME DP - Unbound Medicine ER -